BACE1 and Alzheimer disease: Currently, stage III trials on Verubecestat are continued in patients with early or prodromal stage AD, which might soon provide crucial assessment for the therapeutic efficacy of BACE1 inhibition (or anti-Aβ therapy in general) for AD.